• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD4 和 CD8 T 细胞表达减少可能反映了 COVID-19 患者感染的严重程度，并预测其预后更差：来自荟萃分析的证据。

Less expression of CD4 and CD8 T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: Evidence from a pooled analysis.

机构信息

Department of Laboratory Medicine, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Chongming Branch, Shanghai, China.

Department of Orthopedics, The Second People' Hospital of Hefei, Hefei, Anhui, China.

出版信息

Clin Chim Acta. 2020 Nov;510:1-4. doi: 10.1016/j.cca.2020.06.040. Epub 2020 Jun 27.

DOI:10.1016/j.cca.2020.06.040
PMID:32598880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7319938/
Abstract

This study mainly focused on the very serious COVID-19 epidemic situation at present and provided a new insight for the treatment and monitor of patients with COVID-19. Through this meta-analysis, we could draw a conclusion that less expression of blood CD4 and CD8 T cells count might reflect the severity of infection and often accompanied by a poor prognosis. Hence, we inferred blood CD4+ and CD8+ T cells count could be a promising biomarker for disease assessment and monitor of patients with COVID-19.

摘要

本研究主要针对当前非常严重的 COVID-19 疫情，为 COVID-19 患者的治疗和监测提供了新的视角。通过这项荟萃分析，我们可以得出结论，血液中 CD4 和 CD8 T 细胞计数的减少可能反映了感染的严重程度，并且常常伴有不良预后。因此，我们推断血液 CD4+和 CD8+T 细胞计数可能是 COVID-19 患者疾病评估和监测的有前途的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792e/7319938/3e4d1c34839a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792e/7319938/ba4698d0cc04/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792e/7319938/3e4d1c34839a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792e/7319938/ba4698d0cc04/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792e/7319938/3e4d1c34839a/gr2_lrg.jpg

相似文献

1
Less expression of CD4 and CD8 T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: Evidence from a pooled analysis.CD4 和 CD8 T 细胞表达减少可能反映了 COVID-19 患者感染的严重程度，并预测其预后更差：来自荟萃分析的证据。
Clin Chim Acta. 2020 Nov;510:1-4. doi: 10.1016/j.cca.2020.06.040. Epub 2020 Jun 27.
2
T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019.外周血 T 细胞亚群计数可作为新型冠状病毒肺炎诊断和严重程度预测的鉴别生物标志物。
J Infect Dis. 2020 Jun 29;222(2):198-202. doi: 10.1093/infdis/jiaa252.
3
Increased expression of CD8 marker on T-cells in COVID-19 patients.COVID-19 患者 T 细胞上 CD8 标志物表达增加。
Blood Cells Mol Dis. 2020 Jul;83:102437. doi: 10.1016/j.bcmd.2020.102437. Epub 2020 Apr 13.
4
The changes of the peripheral CD4+ lymphocytes and inflammatory cytokines in Patients with COVID-19.新型冠状病毒肺炎患者外周血 CD4+T 淋巴细胞及炎症因子的变化。
PLoS One. 2020 Sep 25;15(9):e0239532. doi: 10.1371/journal.pone.0239532. eCollection 2020.
5
COVID-19 pneumonia: CD8 T and NK cells are decreased in number but compensatory increased in cytotoxic potential.COVID-19 肺炎：CD8 T 细胞和 NK 细胞数量减少，但细胞毒性潜能代偿性增加。
Clin Immunol. 2020 Sep;218:108516. doi: 10.1016/j.clim.2020.108516. Epub 2020 Jun 20.
6
Decreased T cell populations contribute to the increased severity of COVID-19.T 细胞群体减少导致 COVID-19 病情加重。
Clin Chim Acta. 2020 Sep;508:110-114. doi: 10.1016/j.cca.2020.05.019. Epub 2020 May 13.
7
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.不同疾病严重程度的 COVID-19 患者的实验室检测和宿主免疫。
JCI Insight. 2020 May 21;5(10):137799. doi: 10.1172/jci.insight.137799.
8
A Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes.2019 年冠状病毒病危重症婴儿病例，表现为持续减少的 T 淋巴细胞。
Pediatr Infect Dis J. 2020 Jul;39(7):e87-e90. doi: 10.1097/INF.0000000000002720.
9
Lymphopenia during the COVID-19 infection: What it shows and what can be learned.新冠病毒感染期间的淋巴细胞减少症：所呈现的情况及可从中了解到的信息。
Immunol Lett. 2020 Sep;225:31-32. doi: 10.1016/j.imlet.2020.06.013. Epub 2020 Jun 20.
10
The Science Underlying COVID-19: Implications for the Cardiovascular System.新型冠状病毒肺炎相关科学：对心血管系统的影响。
Circulation. 2020 Jul 7;142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549. Epub 2020 Apr 15.

引用本文的文献

1
Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines.观察 SARS-CoV-2 和 SARS-CoV 的 T 细胞免疫：相信基于表位的疫苗。
Int J Biol Sci. 2023 Aug 6;19(13):4052-4060. doi: 10.7150/ijbs.80468. eCollection 2023.
2
Epithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8 T Cells in Severe/Critical COVID-19.上皮细胞半乳糖凝集素-3诱导严重/危重新冠肺炎患者 CD8 T 细胞线粒体复合物抑制和细胞周期停滞。
Int J Mol Sci. 2023 Aug 14;24(16):12780. doi: 10.3390/ijms241612780.
3
MACC1 as a Potential Target for the Treatment and Prevention of Breast Cancer.

本文引用的文献

1
Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China.新冠肺炎患者中受抑制的 T 细胞介导的免疫：来自中国武汉的临床回顾性研究。
J Infect. 2020 Jul;81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012. Epub 2020 Apr 18.
2
Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu.成都 32 例危重症和 67 例非危重症 COVID-19 的流行病学特征和临床特征。
J Clin Virol. 2020 Jun;127:104366. doi: 10.1016/j.jcv.2020.104366. Epub 2020 Apr 10.
3
Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.
MACC1作为乳腺癌治疗和预防的潜在靶点。
Biology (Basel). 2023 Mar 16;12(3):455. doi: 10.3390/biology12030455.
4
Integrated time-series transcriptomic and metabolomic analyses reveal different inflammatory and adaptive immune responses contributing to host resistance to PRRSV.整合时间序列转录组学和代谢组学分析揭示了不同的炎症和适应性免疫反应，有助于宿主抵抗 PRRSV。
Front Immunol. 2022 Oct 20;13:960709. doi: 10.3389/fimmu.2022.960709. eCollection 2022.
5
Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4+/CD8+ cells in COVID-19 patients.在 COVID-19 患者的 CD4+/CD8+ 细胞中，凋亡细胞和 CTLA-4（CD152）表达细胞的百分比增加。
Medicine (Baltimore). 2022 Sep 23;101(38):e30650. doi: 10.1097/MD.0000000000030650.
6
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.新型冠状病毒肺炎中的外周血T细胞淋巴细胞减少：潜在机制及影响
Immunother Adv. 2021 Jul 2;1(1):ltab015. doi: 10.1093/immadv/ltab015. eCollection 2021 Jan.
7
Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host.SARS-CoV-2 的免疫编辑：病毒与宿主之间的相互关系。
Int Immunopharmacol. 2022 Apr;105:108531. doi: 10.1016/j.intimp.2022.108531. Epub 2022 Jan 10.
8
Association of lymphocyte subsets with mortality in severe COVID-19 pneumonia patients.淋巴细胞亚群与重症 COVID-19 肺炎患者死亡率的关系。
J Clin Lab Anal. 2021 Nov;35(11):e24046. doi: 10.1002/jcla.24046. Epub 2021 Oct 9.
9
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α Expression.通过淋巴细胞亚群分析和单核细胞的诱导型肿瘤坏死因子-α表达预测COVID-19患者的临床结局
Biology (Basel). 2021 Aug 1;10(8):735. doi: 10.3390/biology10080735.
10
Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients.单细胞染色质可及性的表观遗传学景观和 COVID-19 患者 T 细胞的转录组免疫特征。
Front Immunol. 2021 Feb 24;12:625881. doi: 10.3389/fimmu.2021.625881. eCollection 2021.
淋巴细胞亚群（CD4+、CD8+）计数反映感染的严重程度，并可预测新型冠状病毒肺炎患者的临床结局。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.054. Epub 2020 Apr 11.
4
Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus.2019新型冠状病毒感染患者队列中与疾病进展相关的危险因素。
Ann Palliat Med. 2020 Mar;9(2):428-436. doi: 10.21037/apm.2020.03.26. Epub 2020 Mar 17.
5
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
6
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
9
Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score.预测病毒性肺炎患者死亡风险的临床特征：MuLBSTA评分
Front Microbiol. 2019 Dec 3;10:2752. doi: 10.3389/fmicb.2019.02752. eCollection 2019.
10
Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.气道记忆性CD4(+) T细胞介导针对新型呼吸道冠状病毒的保护性免疫。
Immunity. 2016 Jun 21;44(6):1379-91. doi: 10.1016/j.immuni.2016.05.006. Epub 2016 Jun 7.